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0.001). For every 6 patients switching in cohort 1, 10 patients
switched in cohort 2 (hazard ratio: 0.62, 95% CI: 0.57–0.69).
The introduction of generic omeprazole resulted in decreasing
expenditures for omeprazole (−€140 million; −56%) and for all
PPIs (−€52 million; −16%) between 2001–2004. However, some
savings have been missed due to increased switching from the
generic product. Further results will be presented on statins of
which analyses are currently conducted. CONCLUSIONS: After
patent expiry, more patients switch from omeprazole to another
PPI. It is however debatable whether a 5% increase in ‘switch-
ers’ is relevant in the light of enormous decreased expenditures
due to generic substitution.
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ANALYSIS OF COST OF ILLNESS IN THE NETHERLANDS IN
2003: INTEGRATING NATIONAL AND INTERNATIONAL
PERSPECTIVES ON HEALTH CARE COSTS
Slobbe LCJ, Kommer GJ, Polder JJ
National Institute for Public Health and the Environment (RIVM),
Bilthoven,The Netherlands
OBJECTIVES: To determine the demands on health care
resources caused by disease, age and gender and to demonstrate
the importance of the perspective on health expenditure
(national versus international). METHODS: A generic top-down
cost-of-illness analysis was performed for The Netherlands.
Expenditure per provider in 2003 was known for three perspec-
tives on health care costs: the OECD’s System of Health
Accounts (SHA) and two national perspectives. Data on health
care use were collected from 70 registries of which the most
important had national coverage. These were mapped on expen-
diture to estimate cost of illness and enabled analysis in six
dimensions: provider, health care function, source of funding,
age, gender and disease. Outcome measures were total costs and
costs per capita. RESULTS: Mental diseases represent the most
expensive main diagnostic group (22% of total costs). Heart dis-
eases come second (9.2%). Neoplasms come on a 7th place
(4.1%). The three perspectives showed minor differences in
ranking of disease groups. Total costs differed widely between
perspectives: €43.7 to €57.5 billion (9–12% GDP), the higher
estimate based on the perspective of the Dutch National Health
Accounts, the lower on the perspective of the Dutch ministry of
Health. The international SHA-perspective came close in total
costs to the ministry of Health estimate (€45.1 billion), but had
a radical different composition. Cost increase by age, sharply
from 65+ onwards until €50,000 per citizen for the oldest old.
In the SHA-approach the increase is less steep because of the
exclusion of speciﬁc health provisions for Dutch elderly. CON-
CLUSIONS: The perspective on health expenditure has an
important inﬂuence on coi-estimates, especially for per capita
costs and to a lesser extent for the relative expenditure on par-
ticular diseases. Insight in the differences between perspectives
enables better national and international comparisons between
coi-studies.
PHP22
NUTRICORE®: COST-EFFECTIVENESS-ANALYSIS (CE) OF AN
EVIDENCE BASED CLINICAL NUTRITION CONCEPT IN
CORRELATION WITH RELEVANT CLINICAL OUTCOMES IN
HOSPITALIZED MALNOURISHED PATIENTS BY RISK-
ADJUSTMENT OF DIAGNOSIS BASED SEVERITY OF DISEASE
Fischer FJ, Goeke T, Gohlke A
Schellen und Partner GmbH, Düsseldorf, NRW, Germany
Current clinical data show that every third hospitalized patient
in Germany is malnourished. This indicates a need for manda-
tory nutrition status screening and evidence based clinical nutri-
tion. The cost-effectiveness-estimate of this concept has not yet
been evaluated by a diagnosis based severity-of-disease risk-
adjustment. NUTRICORE is the ﬁrst study worldwide, using the
predictive scale of Disease Staging to get valid data on risk-
adjusted clinical and economic outcomes in the ﬁeld of clinical
nutrition research on large patient populations (>10,000).
OBJECTIVES: To show a positive correlation of an evidence
based clinical nutrition concept on clinical and economic out-
comes in malnourished hospitalized patients by risk-adjustment
on severity of disease and corresponding cost-effectiveness-
analysis. METHODS: NUTRICORE SP1 is a prospective con-
trolled interventional multicenter based clinical trial with more
than 10,000 patients from German Hospitals. The nutrition
status of each patient is screened and combined with clinical
data, utilization data and direct costs on the basis of clinical
homogenous patient clusters. The risk adjustment scales can be
run by routine data sets from German inpatient G-DRG system
2006. In the control period starting in June 2006 the effects of
usual nutrition care are documented. Starting the intervention
period in October 2006 an implementation of an interdiscipli-
nary evidence-based guideline for screening and clinical nutrition
will be introduced in each participating hospital. RESULTS:
NUTRICORE SP1 has been piloted in two 600-bed-hospitals in
Germany during 2005, showing a signiﬁcant reduction of costs
for clinical nutrition by €152,544.00 per year for a risk-adjusted
patient population of €38,004 cases in total. CONCLUSIONS:
The study NUTRICORE SP1 is intended to show signiﬁcant clin-
ical improvements and signiﬁcant cost-effectiveness by the imple-
mentation of an evidence based nutrition concept within clinical
homogenous patient groups leading to reduction of Length of
Stay (LOS), Inpatient Mortality, Complications-of-Care, hospi-
tal readmission.
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TIME SERIES ANALYSIS OF PHARMACEUTICAL PUBLIC
EXPENDITURE: EVALUATION OF SUPPLY MEASURES
Magem Luque D, Gilabert i Perramon A
Catalan Health Service, Barcelona, Spain
OBJECTIVES: To analyze the evolution of the pharmaceutical
public expenditure and to evaluate the impact of supply mea-
sures of restraint over its growth. METHODS: Time series analy-
sis through linear autoregressive multivariate models (January
1999–June 2005). Source: monthly pharmaceutical invoices.
Dependent variables: total public expenditure (E), number of
prescriptions adjusted by days (P/d), and average public expen-
diture per prescription (E/P). Independent variables analyzed:
trend, seasonal variation, cycles, number of days and lags when
necessary. Impacts analyzed: introduction of maximum margins
for wholesalers and chemists’ and discounts over chemists’
turnovers (D), and introduction of two reference pricing groups
(RPG1 & RPG2 respectively). Lags are also introduced when
residual autocorrelation occurs. Models are validated through
normal contrast and no-correlation of residual. RESULTS:
Adjusted R2 are 0.818, 0.684 and 0.814 in E, P/d and E/P when
trend is considered as unique variable. There are no seasonal
variation at any time series (p > 0.1) when this variable is related
to four seasons as a categorical variable. However, August has
been entered in E and P/d models as a dichotomic variable (p <
0.0001 & p < 0.01). Number of days also entered in E model 
(p < 0.0001). Annual cycle is observed in P/d and E/P model 
(p < 0.05) and half-yearly and cuatrimestral cycles also entered
in P/d model (p < 0.05). Two supply measures present impacts
at the short term. D has entered in the three models: E (p < 0.001;
Beta: −8,733,966), P/d (Beta: −13,100) and E/P (Beta: −0.18) 
(p < 0.05 both). RPG2 has been also considered in E (Beta: 
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−4,339,412) and E/P (Beta: −0.16) (p < 0.05 both). Final adjusted
R2: E: 0.937; P/d: 0.918; E/P: 0.906. CONCLUSIONS: trend is
the most signiﬁcant variable in the three models and when an
impact is statistically signiﬁcant, it seems not to present long-
term sustainability because these supply measures have a short-
term impact.
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THE COST OF ILLNESS: SPAIN 1980–2000
Gisbert R1, Brosa M2
1Universitat de Vic,Vic, Spain, 2Oblikue Consulting, Barcelona, Spain
OBJECTIVE: To distribute the total health spending in Spain for
the years 1980–2000 among the seventeen ICD-9-CM cate-
gories. The study aimed to gather data for 1980, 1985, 1990,
1993, 1996, and 2000 in order to obtain a baseline from which
to analyse the evolution of spending over time. METHODS: The
method used was the top-down approach, starting with overall
spending ﬁgures and, by means of various procedures, breaking
them down to the desired level. The method comprised two
stages. First, health spending was distributed according to the
different types of health care: hospital care, primary care, drugs,
and others. Second, the spending for each type of care was dis-
tributed among the ICD-9-CM categories. The base unit varied
according to each level: admissions for hospital care, appoint-
ments for primary care, and consumption per therapeutic sub-
group for drug treatment. RESULTS: In the period 1980–2000
health spending was concentrated into three ICD-9 categories:
VII, VIII and IX (37.4% of spending in 1980 and 40.1% of
spending in 2000). In terms of their relative rankings, category
VII was second in 1980 (10.1%) but had moved into ﬁrst place
by the year 2000 (17.6%), showing one of the highest growth
rates for the period. Category VIII (diseases of the respiratory
system) was ranked ﬁrst in 1980 (17.6%) but had fallen to
second place by 2000 (13.2%). As regards the third category (IX:
diseases of the digestive system) its relative position hardly
varied: 9.7% in 1980 and 9.3% in 2000. The results also show
that although the internal composition of each category (per-
centage of each type of health care) may vary widely, few im-
portant variations were observed between 1980 and 2000.
CONCLUSIONS: The information provided may be of use to
health managers and planners and it also establishes reference
baselines for cost-of-illness studies of speciﬁc pathologies.
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EXPENDITURES ON DRUGS IN DEVELOPED EUROPEAN
COUNTRIES
Praznovcova L, Ivanovic N
Charles University, Hradec Kralove, Czech Republic
OBJECTIVES: The article is transversal comparison expenditure
analysis for drugs of 23 economicly developed european coun-
tries that are members of OECD. The data are related to year
2003, ﬁnancial indicators are expressed in dollars. METHODS:
Drug expenses are analysed in relation with those variables: GDP
per 1 inhabitant, health care expenses per 1 inhabitant, number
of physicians in praxis per 1000 inhabitants, proportion of
inhabitants of the age 65 years or more. Among all the variables
medium strong to strong relation was observed, determination
index between drug expenditure per 1 inhabitant and actual
number of active physicians and proportion of inhabitants of the
age 65 years or more reached the value of 51%. RESULTS:
Average drug expenditure per 1 inhabitant of the given year were
343 dollars, absolute average year growth in the years period
1995–2003, 19,4 dollars. Propotional expenditure average of
health care from GDP reached in the year 2003 value of 8,32%,
expenditure proportion on drugs from GDP was 1,37% from
health care expenditure 16,9%. By cluster analysis signiﬁcant
relation between drug expenditure and number of general physi-
cians and elderly inhabitants was determined. CONCLUSION:
Lower drug expenditures have countries with lower economical
efﬁciency, but also economicly developed European countries
where systemic regulations are applied, directed towards main
activators affecting the drug’s consumption and price.
PHP26
SUPPLY SIDE COST-CONTAINMENT IN GERMANY: WIN
SOME, LOSE SOME
Carrera P1, Bridges J2, Kinder K3
1University of Heidelberg, Heidelberg, Baden-Wuertember, Germany,
2Johns Hopkins University, Baltimore, MD, USA, 3Johns Hopkins
University, Nidderau, Germany
Until the late 1980s, the German health care machine worked
well. Since then, it has been challenged the restructuring of the
health care system of the former East Germany, economic down-
turn and changing demographics. OBJECTIVES: To analyze the
reforms in ﬁnancing and reimbursement in the German health
care system over the past 15 years to guide health reforms 
elsewhere. METHODS: A policy and evaluation analysis was
applied to the literature on health ﬁnancing reforms in Germany
to understand the contexts of the measures and their effects. To
understand the impact of the policies, a scale was developed to
assess the trajectory of the health care system as a result of the
reforms based on the principles of solidarity and subsidiarity on
which the German health care system was built. RESULTS: Clas-
siﬁcation of 12 reimbursement and ﬁnancing measures indicates
a shift away from the status quo from the solidarity-subsidiarity
dyad towards either the solidarity-governmental interference or
Eigenverantwortung (personal responsibility)-subsidiarity dyad.
Unfortunately, despite their collective potential of far-reaching
impact and long-term success, deﬁcit in operating mechanism(s)
and inconsistencies have hindered the supply-side cost-
containment measures of the past 15 years. CONCLUSION: Just
as a change in the environment requires new tools to address
challenges faced by the system, so does the approach to insti-
tuting reforms call for rethinking. While in the politics of health
policy evolutionary reforms may make more sense than radical
reforms, beyond evolutionary reforms which have produced only
modest results the sustainability of the ﬁnancing of the system
calls for radical reforms.
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THE ANALYSIS OF TEMPORARY WORK DISABILITY FOR THE
PERIOD OF OVER 30 DAYS IN THE REPUBLIC OF SERBIA
Perovich S
Republic Health Insurance Institute, Belgrade, Serbia and Montenegro
OBJECTIVES: Analysis of utilization of the right to sick leaves
of the beneﬁciaries of the Republic Health Insurance Insti-
tute(RHII) in the period from January to September 2005, lasting
more that 30 days, analysis of the reasons for sick leaves and
suggested measures for more efﬁcient control over the rights to
beneﬁts, upgrading of utilization and guaranteeing the rights,
providing equal rights to all beneﬁciaries,and abuse reduction.
METHODS: Statistic data processing by uniform statistic forms
containing data on all medical commissions, classiﬁcation of
groups of deseases according to the ICD-10. RESULTS: The total
number of beneﬁciaries with temporary work disability was
263,825, 50,316 were enabled, 213,509 were given extensions
and 28,387 beneﬁciaries were sent to DMC. The most common
reasons for sick leaves were: vascular deseases 12.73%, bones,
joints & muscles system 11.36%, mental and behaviour disor-
ders 10.85%, injuries—distorsions and fractures 9.05%, tumors
